Show simple item record

dc.contributor.authorBranda, J.A.
dc.contributor.authorBody, B.A.
dc.contributor.authorBoyle, J.
dc.date.accessioned2019-06-21T18:46:32Z
dc.date.available2019-06-21T18:46:32Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85044243912&doi=10.1093%2fcid%2fcix943&partnerID=40&md5=238cf3d64c6f16617a97da1d367dc257
dc.identifier.urihttp://hdl.handle.net/10713/9761
dc.description.abstractThe cause of Lyme disease, Borrelia burgdorferi, was discovered in 1983. A 2-tiered testing protocol was established for serodiagnosis in 1994, involving an enzyme immunoassay (EIA) or indirect fluorescence antibody, followed (if reactive) by immunoglobulin M and immunoglobulin G Western immunoblots. These assays were prepared from whole-cell cultured B. burgdorferi, lacking key in vivo expressed antigens and expressing antigens that can bind non-Borrelia antibodies. Additional drawbacks, particular to the Western immunoblot component, include low sensitivity in early infection, technical complexity, and subjective interpretation when scored by visual examination. Nevertheless, 2-tiered testing with immunoblotting remains the benchmark for evaluation of new methods or approaches. Next-generation serologic assays, prepared with recombinant proteins or synthetic peptides, and alternative testing protocols, can now overcome or circumvent many of these past drawbacks. This article describes next-generation serodiagnostic testing for Lyme disease, focusing on methods that are currently available or near-at-hand. Copyright The Author(s) 2017.en_US
dc.description.sponsorshipResearch in this area was supported in part by the Intramural and Extramural Research Programs of the National Institutes of Health (NIH), NIAID.en_US
dc.description.urihttps://dx.doi.org/10.1093/cid/cix943en_US
dc.language.isoen-USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical Infectious Diseases
dc.subjectBorrelia burgdorferien_US
dc.subjectDiagnosisen_US
dc.subjectLyme diseaseen_US
dc.subjectSerologyen_US
dc.subjectTestsen_US
dc.titleAdvances in Serodiagnostic Testing for Lyme Disease Are at Handen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/cix943
dc.identifier.pmid29228208


This item appears in the following Collection(s)

Show simple item record